This special issue reviews various aspects of angiogenesis in hematological diseases and considers perspectives of new therapeutic approaches. The initial chapters focus on the role of mediators of angiogenesis, the effect of hematopoietic growth factors on endothelial cell functions and on the relationship between angiogenesis and hematopoiesis. Subsequently, the importance of angiogenesis in the pathophysiology of several hematological diseases is discussed. Besides multiple myeloma - the first disease in which the role of angiogenesis has been ascertained - evidence is provided on the relevance of dysregulated angiogenesis in acute leukemias, myelodysplastic syndromes, myeloproliferative disorders and non-Hodgkin’s lymphoma. In all these diseases, neo-angiogenesis is indicated by the increased vascularity in bone marrow and high levels of several angiogenic factors. The value of these factors in the clinical outcome of hematological diseases and the rationale for the use of anti-angiogenic treatments as a new therapeutical approach are addressed. Finally, a model of aberrant angiogenesis as the cause of an hereditary hemorrhagic disorder is described.
A valuable resource for any hematologist, this publication will also be of interest to researchers and clinicians in oncology and internal medicine.